InMed Pharmaceuticals Inc.
INM
$0.88
-$0.01-1.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 820.20K | 1.12M | 1.30M | 1.26M | 1.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 820.20K | 1.12M | 1.30M | 1.26M | 1.11M |
| Cost of Revenue | 636.00K | 717.00K | 728.10K | 1.09M | 650.80K |
| Gross Profit | 184.20K | 403.20K | 576.70K | 175.60K | 460.90K |
| SG&A Expenses | 1.62M | 1.53M | 2.25M | 1.33M | 1.72M |
| Depreciation & Amortization | 53.20K | 53.20K | 52.80K | 52.30K | 53.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.94M | 2.88M | 3.15M | 3.38M | 3.32M |
| Operating Income | -2.12M | -1.76M | -1.84M | -2.12M | -2.21M |
| Income Before Tax | -2.03M | -1.73M | -1.79M | -2.12M | -2.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.03M | -1.73M | -1.79M | -2.12M | -2.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.03M | -1.73M | -1.79M | -2.12M | -2.58M |
| EBIT | -2.12M | -1.76M | -1.84M | -2.12M | -2.21M |
| EBITDA | -2.07M | -1.71M | -1.79M | -2.06M | -2.15M |
| EPS Basic | -0.72 | -0.44 | -1.20 | -1.94 | -3.64 |
| Normalized Basic EPS | -0.45 | -0.27 | -0.75 | -1.21 | -2.28 |
| EPS Diluted | -0.72 | -0.44 | -1.20 | -1.94 | -3.64 |
| Normalized Diluted EPS | -0.45 | -0.27 | -0.75 | -1.21 | -2.28 |
| Average Basic Shares Outstanding | 2.80M | 3.95M | 1.49M | 1.10M | 706.50K |
| Average Diluted Shares Outstanding | 2.80M | 3.95M | 1.49M | 1.10M | 706.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |